Long-term drug delivery implant for select chronic disorders

Titan Pharmaceuticals’ ProNeura implant offers an alternative to oral administration by providing stable medication levels for up to 12 months. To download the full article, please sign in.

Page of
Go to the profile of Titan Pharmaceuticals

Titan Pharmaceuticals

Titan is a specialty pharmaceuticals company that develops therapeutics for select chronic diseases utilizing its innovative, long-term, continuous drug delivery platform ProNeura. ProNeura enhances patient care by providing non-fluctuating, stable levels of medication in the blood for three months up to one year, potentially offering health and safety advantages over oral administration and improving medical outcomes. Titan's lead product candidate, Probuphine, is a six-month buprenorphine implant for the maintenance treatment of opioid addiction. A New Drug Application for Probuphine was accepted by the U.S. Food and Drug Administration in September 2015, with an agency action date of February 27, 2016. If approved, Probuphine would be the first marketed product to provide maintenance treatment of opioid addiction continuously for six months following a single administration procedure. Probuphine has the potential to increase patient compliance and decrease the risk of diversion. Titan is in the early stages of a product development program utilizing its validated long-term drug delivery platform ProNeura for the treatment of Parkinson's disease and is evaluating the feasibility of additional product candidates that would be suitable for the treatment of several chronic diseases, including hormonal deficiency, type 2 diabetes, attention deficit hyperactivity disorder, benign prostate hyperplasia and others. In addition to developing its pipeline internally, Titan is exploring joint development projects and licensing opportunities for its ProNeura technology to other companies, both in the US and globally.

Comments are disabled